Moderna, Inc. (MRNA)

Market Cap	13.09B
Revenue (ttm)	3.24B
Net Income (ttm)	-3.56B
Shares Out	386.62M
EPS (ttm)	-9.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,963,372
Open	34.31
Previous Close	34.17
Day's Range	33.51 - 34.86
52-Week Range	29.25 - 170.47
Beta	1.86
Analysts	Hold
Price Target	54.82 (+61.85%)
Earnings Date	May 1, 2025

About MRNA

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 7, 2018
• Employees: 5,800
• Stock Exchange: NASDAQ
• Ticker Symbol: MRNA
• Website: https://www.modernatx.com

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Analyst Forecast

According to 20 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $54.82, which is an increase of 61.85% from the latest price.

Price Target

$54.82

(61.85% upside)

Analyst Consensus: Hold